CancerAdultAgedFemaleHumansMale
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke, John C Rhee, Saiama N Waqar, Geoffrey I Shapiro, James Cleary, Diwakar Davar, Timothy F Burns, Rashmi Verma, Manik Amin, Leonard Appleman, Kristen K Ciombor
Published: 202510.1002/cncr.70157
Abstract
BACKGROUND: Ataxia telangiectasia and Rad3-related (ATR) inhibition with berzosertib potentiates the efficacy of irinotecan in preclinical models. The authors hypothesize that this combination is well tolerated, modulates the DNA damage response to i…
Preview only. Read the full abstract at the source